SDGRClinical Trials•businesswire•June 12, 2025 at 11:00 AM

Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

Sentiment:Positive (80)

MILAN--(BUSINESS WIRE)--Schrödinger announces encouraging initial clinical data from its ongoing Phase 1 dose-escalation study of SGR-1505.

Read the full article from the original source for complete details and context.

Article published on June 12, 2025 by businesswire